The global C-reactive protein (CRP) testing market continues to witness robust expansion as early disease detection and preventive healthcare become central to clinical practice worldwide. The market has evolved rapidly in response to growing emphasis on point-of-care diagnostics, chronic disease surveillance, and inflammation-based disease management. The global C-reactive protein (CRP) testing market was valued at USD 2.9 billion in 2024 and is projected to grow at a CAGR of 8.80% from 2025 to 2034, reflecting strong momentum driven by rising cardiovascular and infectious disease burdens, enhanced diagnostic infrastructure, and continuous advancements in immunoassay technologies. CRP testing, a biomarker assay that quantifies inflammatory response and tissue damage, has emerged as an essential diagnostic tool across clinical laboratories and outpatient settings, supporting better clinical decisions in conditions ranging from sepsis and pneumonia to autoimmune disorders and atherosclerosis.

North America remains a major contributor to global revenue due to high testing penetration, well-established healthcare systems, and strong insurance coverage for diagnostic services. According to the U.S. Centers for Disease Control and Prevention (CDC), chronic inflammatory diseases such as arthritis and cardiovascular disorders affect more than 60 million Americans, significantly boosting demand for CRP testing in both primary and secondary care. The region benefits from early adoption of high-sensitivity CRP (hs-CRP) assays for cardiovascular risk assessment, particularly in the United States where the Food and Drug Administration (FDA) has approved multiple hs-CRP tests for clinical use. The Centers for Medicare & Medicaid Services (CMS) have expanded reimbursement for such diagnostics, reinforcing the role of CRP testing as a routine clinical measure. The U.S. diagnostic landscape is also defined by the integration of laboratory automation and digital connectivity, enabling faster turnaround times and improved data traceability. Meanwhile, Canada continues to strengthen preventive healthcare frameworks through provincial health programs that emphasize biomarker testing for early detection of chronic inflammation and metabolic disorders. The presence of leading diagnostic firms and reference laboratories, along with continuous government funding in healthcare R&D under initiatives like the National Institutes of Health (NIH) Precision Medicine Program, ensures sustained market growth in the region.

Europe also represents a significant hub for the CRP testing market, supported by advanced clinical infrastructure and an expanding elderly population susceptible to inflammatory and infectious conditions. Eurostat data indicate that nearly 21% of the European Union population is aged 65 years and above, a demographic shift driving the need for chronic disease management and monitoring tools. European healthcare authorities have increasingly integrated CRP testing into primary care workflows, particularly for antibiotic stewardship programs aimed at curbing unnecessary prescriptions. The United Kingdom’s National Institute for Health and Care Excellence (NICE) has recommended CRP testing to guide antibiotic treatment in lower respiratory tract infections, illustrating its clinical relevance in public health policy. Germany, France, and the Netherlands are witnessing rising adoption of rapid and point-of-care CRP testing devices in outpatient and emergency settings, driven by national efforts to reduce diagnostic turnaround time and healthcare costs. The European Commission’s Horizon Europe and Digital Health initiatives are also fostering research into next-generation immunoassays and integrated biosensors, further stimulating innovation across the market. Additionally, the tightening of In Vitro Diagnostic Regulation (IVDR) compliance requirements across the EU is reshaping the competitive environment, encouraging companies to improve test accuracy, standardization, and traceability across the diagnostic continuum.

The Asia Pacific region is emerging as the fastest-growing market, propelled by rapid healthcare expansion, increasing chronic disease prevalence, and public investments in laboratory infrastructure. Data from Japan’s Ministry of Health, Labour and Welfare (MHLW) and India’s Ministry of Health and Family Welfare (MoHFW) highlight a substantial rise in the incidence of cardiovascular and metabolic disorders, which are major end-use drivers for CRP testing. China’s healthcare modernization initiatives under the Healthy China 2030 strategy have accelerated diagnostic test adoption, particularly in secondary and tertiary hospitals. The government’s push for localized production of diagnostic reagents and instruments under the Made in China 2025 initiative is stimulating domestic manufacturing capacity. Meanwhile, India’s expanding diagnostic ecosystem, bolstered by the National Health Mission and Ayushman Bharat scheme, is improving access to affordable CRP testing in both public and private laboratories. Japan continues to lead regional innovation, leveraging its strong biotechnology sector and favorable regulatory frameworks to advance automated and multiplex testing solutions. Growing demand for rapid testing kits in community health programs, along with the expansion of private diagnostic networks in Southeast Asia, is further diversifying the market’s regional footprint. The convergence of AI-driven data analytics and cloud-based diagnostic systems across the Asia Pacific is enabling early detection and remote monitoring, addressing healthcare access gaps in rural areas while improving patient outcomes.

Read More @ https://www.polarismarketresearch.com/industry-analysis/c-reactive-protein-testing-market

The primary drivers of the CRP testing market include increasing awareness of inflammatory biomarkers in disease management, rising chronic disease incidence, and expanding point-of-care testing adoption. Government-backed initiatives promoting preventive healthcare, coupled with the integration of CRP testing into population health programs, continue to elevate demand. The U.S. Food and Drug Administration and the European Medicines Agency have accelerated approvals for innovative immunoassay analyzers and high-sensitivity CRP kits, enhancing market accessibility. However, regulatory and operational challenges persist. Variations in reimbursement policies across regions, disparities in laboratory infrastructure, and limited awareness in developing economies can restrict adoption. Cost constraints in low-income countries, especially where out-of-pocket expenditure remains high, further limit patient access to advanced testing technologies.

Despite these challenges, emerging opportunities in decentralized diagnostics, home-based health monitoring, and wearable biosensors present significant growth potential. Companies are increasingly focusing on portable CRP analyzers that provide rapid results at the point of care, reducing the need for centralized laboratory processing. Trends indicate growing integration of CRP testing with telemedicine and remote patient monitoring platforms, a development aligned with the World Health Organization’s (WHO) strategic vision for digital health expansion. Moreover, the proliferation of automated analyzers capable of multi-parameter testing is transforming laboratory efficiency, lowering per-test costs, and ensuring consistent data accuracy.

The competitive landscape of the global C-reactive protein testing market is characterized by a mix of multinational diagnostics firms and emerging biotech companies. Strategic collaborations, regulatory compliance upgrades, and regional manufacturing partnerships remain key strategies for sustaining market presence in an increasingly regulated and technology-driven environment.

Major companies holding significant market share include:

• Abbott Laboratories
• Thermo Fisher Scientific Inc.
• F. Hoffmann-La Roche Ltd.
• Siemens Healthineers AG
• Danaher Corporation
• Beckman Coulter Inc.
• Randox Laboratories Ltd.
• Ortho Clinical Diagnostics
• Bio-Rad Laboratories Inc.
• Euroimmun AG